SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 3-YEAR EFFICACY AND SAFETY RESULTS FROM PHASE 3 FUTURE 1 TRIAL

被引：7

作者：

Mease, P. J. ^{[1
,2
]}

Kavanaugh, A. ^{[3
]}

Reimold, A. ^{[4
]}

Tahir, H. ^{[5
]}

Rech, J. ^{[6
]}

Hall, S. ^{[7
]}

Geusens, P. ^{[8
,9
]}

Pascale, P. ^{[10
]}

Delicha, E. M. ^{[10
]}

Pricop, L. ^{[11
]}

Mpofu, S. ^{[10
]}

机构：

[1] Swedish Med Ctr, Seattle, WA USA

[2] Univ Washington, Seattle, WA 98195 USA

[3] UC San Diego Sch Med, La Jolla, CA USA

[4] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA

[5] Barts Hlth NHS Trust, London, England

[6] Univ Erlangen Nurnberg, Erlangen, Germany

[7] Monash Univ, Melbourne, Vic, Australia

[8] Univ Hasselt, Hasselt, Belgium

[9] Maastricht Univ Hosp, Maastricht, Netherlands

[10] Novartis Pharma AG, Basel, Switzerland

[11] Novartis Pharmaceut, E Hanover, NJ USA

来源：

关键词：

D O I：

10.1136/annrheumdis-2017-eular.1260

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

SAT0470

引用

页码：952 / 953

页数：2